$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Methodologies to assess cPK after topical drug product application have expanded from classical in vitro permeation testing (IVPT) studies1,2,3,4,5 and tape-stripping6,7,8 to additional methodologies such as open-flow microperfusion or dermal microdialysis9,10,11,12,13,14. There are potentially various local sites of therapeutic action depending on the disease of interest. Hence, there may be a corresponding number of methodologies to assess the rate and extent to which an API gets to the intended local site of action. While each of the aforementioned methodologies has its advantages, the major disadvantage is the lack of microscale cPK information (i.e., the inability to visualize where the API goes and how it permeates).
One noninvasive methodology of interest to estimate topical BA and BE is CRI, which can be broken down into two imaging modalities: CARS and SRS microscopy. These coherent Raman methods enable chemically specific imaging of molecules via nonlinear Raman effects. In CRI, two laser pulse trains are focused and scanned within a sample; the difference in energy between the laser frequencies is set to target vibrational modes specific to the chemical structures of interest. As CRI processes are nonlinear, a signal is only generated at the microscope focus, allowing for three-dimensional pharmacokinetic tomographic imaging of the tissue. In the context of cPK, CARS has been used to obtain tissue structural information, such as the location of lipid-rich skin structures15. In contrast, SRS has been utilized to quantify molecular concentration as its signal is linear with concentration. For ex vivo skin specimens, it is advantageous to carry out CARS in the epi-direction16 and SRS in transmission mode17. Therefore, tissue samples that are thin will allow for SRS signal detection and quantification.
As a model tissue, the nude mouse ear presents several advantages with minor drawbacks. One advantage is that the tissue is already ~200-300 µm in thickness and does not require further sample preparation. In addition, several skin stratifications are seen by axially focusing through one field of view (e.g., stratum corneum, sebaceous glands (SGs), adipocytes, and subcutaneous fat)16,18. This allows for preliminary preclinical estimation of cutaneous permeation pathways and topical BA estimates before moving to human skin samples. However, the nude mouse model presents limitations such as difficulty in extrapolation to in vivo scenarios due to differences in skin structure19. While the nude mouse ear is an excellent model to obtain preliminary results, the human skin model is the gold standard. Although there have been various commentaries on the suitability and applicability of frozen human skin to accurately recapitulate in vivo permeation kinetics20,21,22, the use of frozen human skin is an accepted method for the evaluation of in vitro API permeation kinetics23,24,25. This protocol visualizes various skin layers in mouse and human skin while quantifying API concentrations within lipid-rich and lipid-poor structures.
While CRI has been utilized across numerous fields to specifically visualize compounds within tissues, there have been limited efforts investigating the cPK of topically applied drug products. To evaluate the topical BA/BE of topical products using CRI, it is necessary to first have a standardized protocol in place to make accurate comparisons. Previous efforts using CRI for drug delivery to the skin have demonstrated variability within the data. As this is a relatively new application of CRI, establishing a protocol is critical to obtain reliable results18,26,27. This approach only targets one specific wavenumber in the biological silent region of the Raman spectrum. However, most APIs and inactive ingredients have Raman shifts within the fingerprint region. This has previously posed challenges due to the inherent signal arising from the tissue in the fingerprint region. Recent laser and computational advances have removed this barrier, which can also be utilized in combination with the approach presented here28. This approach presented here allows for the quantification of an API, which has a Raman shift in the silent region (2,000-2,300 cm-1). This is not limited to the physiochemical properties of the drug, which might be the case for some previously mentioned cPK monitoring methodologies29.
The protocol must reduce sample-to-sample variability in skin thickness for various preparations, as thick human skin samples will produce minimal signal after drug product application due to light scattering by the thick sample. A goal of this manuscript is to present a tissue preparation methodology that assures reproducible imaging standards. In addition, the CRI system is setup as described to reduce potential sources of error as well as minimize signal-to-noise. However, this paper will not discuss the guiding principles and technical merits of the CRI microscope as this has been previously covered30. Finally, the extensive data analysis procedure is explored to allow for interpretation of the results to determine an experiment's success or failure.